J. Davide

G. Prendergast, R. Diehl, A. Kral, 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.

T. Ciccarone, A. Kral, J. Davide, 1996, Journal of medicinal chemistry.

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment.

S. Stirdivant, A. Sachs, J. Davide, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.

D. Nalin, E. Ellerbeck, J. Davide, 1992, Vaccine.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

A. Kral, D. Heimbrook, J. Davide, 2001, Cancer research.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

C. Fuchs, P. Deutsch, Sunil Sharma, 2002, Molecular cancer therapeutics.

CHAPTER 20 – Preparation of Ribonucleic Acid from Physarum polycephalum

J. Davide, P. Melera, 1982 .

Phenotypic expression in Escherichia coli and nucleotide sequence of two Chinese hamster lung cell cDNAs encoding different dihydrofolate reductases

K. Scotto, J. Davide, C. Hession, 1984, Molecular and Cellular Biology.

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

G. Prendergast, J. Davide, N. Kohl, 1994, Molecular and cellular biology.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

J. Davide, J. Lewis, K. Weinhold, 1990, Science.

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

A. Kral, J. Davide, N. Kohl, 1995, Nature Medicine.

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

G. Prendergast, J. Davide, P. Lebowitz, 1995, Molecular and cellular biology.

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.

J. Huff, J. Davide, N. Kohl, 1999, Journal of medicinal chemistry.

Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.

G. Prendergast, R. Wechsler-Reya, J. Davide, 1996, Cancer research.

Antifolate-resistant Chinese Hamster Cells. mRNA directed overproduction of multiple dihydrofolate reductases from a series of independently derived sublines containing amplified dihydrofolate reductase genes.

K. Scotto, J. Davide, J. L. Biedler, 1982, The Journal of biological chemistry.

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.

D. Nalin, S. Lemon, J. Davide, 1997, The Journal of infectious diseases.

Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.

A. Sachs, Weikang Tao, J. Davide, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines.

J. Davide, P. Melera, H. Oen, 1988, Journal of Biological Chemistry.

Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F.

R. D. Keys, J. Davide, J. Lewis, 1993, Journal of hepatology.

Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Youwei Yan, P. Coleman, Christopher D. Cox, 2008, Journal of medicinal chemistry.

An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis

R. Diehl, Weikang Tao, Vicki J South, 2006, Molecular and Cellular Biology.

The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.

J. Davide, R. Lobell, J. Gibbs, 2002, Bioorganic & medicinal chemistry letters.